BLCO — Bausch & Lomb Corp

NYSE · Unknown · Unknown · CIK 1860742 ·
Last close
$17.32
Market Cap
$6.19B
52W High
$17.77
52W Low
$14.65
ADV30
414,866
Next earnings
2026-10-28
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 1,394,000,000 867,000,000 108,000,000 -14,000,000 13,859,000,000 367,000,000 7,415,000,000
Mar 2026 1,244,000,000 761,000,000 59,000,000 -71,000,000 13,780,000,000 268,000,000 7,328,000,000
Dec 2025 1,405,000,000 872,000,000 158,000,000 -58,000,000 14,022,000,000 383,000,000 7,503,000,000
Sep 2025 1,281,000,000 771,000,000 80,000,000 -28,000,000 13,832,000,000 310,000,000 7,332,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$458,000,000
Investing CF
$-466,000,000
Financing CF
$118,000,000
CapEx
$-321,000,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.48
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,016,000,000
Inventory
$999,000,000
Receivables
$1,160,000,000
ST Investments
EBIT TTM
$324,000,000
Pretax Income TTM
$-65,000,000
Interest Exp TTM
$389,000,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,324,000,256
EBITDA
$816,000,000
Free Cash Flow
$323,000,000
Enterprise Value
$11,002,101,760
Total Cash
$367,000,000
Total Debt
$5,114,999,808
Shares Out
357,165,246
Trailing EPS
$-0.48
Book Value
$18.09
ROE
-2.5%
ROA
1.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 5,101,000,000 188,000,000 -360,000,000 14,022,000,000 7,503,000,000 283,000,000
Dec 2024 4,791,000,000 206,000,000 -317,000,000 13,469,000,000 6,925,000,000 232,000,000
Dec 2023 4,146,000,000 204,000,000 -260,000,000 13,442,000,000 6,522,000,000 -17,000,000
Dec 2022 3,768,000,000 220,000,000 6,000,000 11,144,000,000 4,043,000,000 345,000,000

TTM Snapshot

Revenues TTM
$4,094,000,000
NetIncome TTM
$-38,000,000
OpCashFlow TTM
$0
Assets (Latest)
$13,469,000,000
Forward EPS
$1.09

Peers — same industry

TickerNameMarket CapLastDaily %
SLFPY STANDARD LIFE PLC $6.26B $13.60
EXP EAGLE MATERIALS INC $6.27B $204.25
ST Sensata Technologies Holding plc $6.11B $41.96
MAUTF Montage Gold Corp. $6.08B $15.04
MBSHY Mitsubishi Gas Chemical Company, Inc./ADR $6.31B $32.35

News headlines (Yahoo Finance, 1h cache)

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
2026-08-25 16:54 · Yahoo
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
2026-08-25 15:53 · Yahoo
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
2026-08-25 01:01 · Yahoo
Bausch + Lomb Plans to Advance Dual-Action Eye Drop Targeting Evaporative and Inflammatory Dry Eye Disease to Phase 3
2026-08-24 21:38 · Yahoo
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
2026-08-24 20:30 · Yahoo
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
2026-08-13 13:00 · Yahoo
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
2026-08-06 11:04 · Yahoo
Bausch + Lomb (BLCO) Lifts 2026 Revenue Guidance, Is The Stock Still 57% Undervalued?
2026-07-31 22:09 · Yahoo
Bausch + Lomb Corporation Q2 2026 Earnings Call Summary
2026-07-30 12:30 · Yahoo
COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?
2026-08-18 16:39 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.